NEW YORK – Children's Hospital of Philadelphia (CHOP) and Gustave Roussy in France have received $1.3 million to conduct parallel Phase III trials of Pfizer's ALK inhibitor lorlatinib (Lorbrena) in ALK-mutated, pediatric neuroblastoma patients.
The grant was awarded by a group of research charities, led by Solving Kids' Cancer UK and Solving Kids' Cancer US. The funds will be split between CHOP and Gustave Roussy and spread over four years.